Form 8-K filed
0000872589-26-000032
Item 2.02 · Results of Operations and Financial Condition
Item 9.01 · Financial Statements and Exhibits
Official EDGAR filingCash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Form 8-K filed — 8-K; 2026-10-30.
Based on data through Oct 30, 2026
Next verified event · FDA target date
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Announced Oct 30, 2026 · Announced window
Official announcementThe FDA accepted for review the resubmission of the BLA for Ordspono™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027.
FDA target date
Announced Oct 30, 2026 · Announced window
Official announcementIn October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications. The positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. The European Commission (EC) is expected to make a final decision in the coming months. There is also a supplemental Biologics License Application (sBLA) under review by the U.S. Food and Drug Administration (FDA), which has a target action date in March 2027.
0 programs · 0 verified studies
No verified studies linked yet.
806 unverified sponsor matches remain unlinked.
0000872589-26-000032
Item 2.02 · Results of Operations and Financial Condition
Item 9.01 · Financial Statements and Exhibits
Official EDGAR filing0001104659-26-113895
Item 1.01 · Entry into a Material Definitive Agreement
Item 2.02 · Results of Operations and Financial Condition
Item 8.01 · Other Events
Official EDGAR filing0001104659-26-112340
Item 5.02 · Departure or Appointment of Directors or Officers; Compensatory Arrangements
Item 9.01 · Financial Statements and Exhibits
Official EDGAR filing